2018
DOI: 10.1007/s40265-018-0872-z
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Belimumab (Benlysta) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE). Belimumab is approved in the EU, the USA and other countries as add-on therapy in adult patients with active, autoantibody-positive SLE despite standard therapy. In phase III trials, treatment with IV or SC belimumab plus standard therapy was effective … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
61
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 96 publications
(64 citation statements)
references
References 44 publications
2
61
0
1
Order By: Relevance
“…Ofatumumab is a more potent CD20 + B cell depleter and may replace rituximab in patients with drug hypersensitivity 88,239 . Another agent, belimumab (which targets B cell-activating factor), is an established maintenance therapy in systemic lupus erythematosus and reduces proteinuria in lupus nephritis 240 and might control B cell activity also in other forms of nephrotic syndrome.…”
Section: Managementmentioning
confidence: 99%
“…Ofatumumab is a more potent CD20 + B cell depleter and may replace rituximab in patients with drug hypersensitivity 88,239 . Another agent, belimumab (which targets B cell-activating factor), is an established maintenance therapy in systemic lupus erythematosus and reduces proteinuria in lupus nephritis 240 and might control B cell activity also in other forms of nephrotic syndrome.…”
Section: Managementmentioning
confidence: 99%
“…It is generally well tolerated with low rates of immunogenicity. Belimumab in combination with standard therapy reduces the overall disease activity and the incidence and severity of flares, has steroid-sparing effects, and can maintain disease control for at least 10 years ( 164 ). Interestingly, despite its clinical efficiency, belimumab only partly inhibits the production of IgG-autoantibodies.…”
Section: Alternative B Cell Targeting Approachesmentioning
confidence: 99%
“…The BAFF-directed antibody belimumab is currently approved for treatment-resistant SLE in adults, reducing flares and overall disease activity when used in combination with standard therapy. 101 However, it is known that belimumab only partially inhibits the production of IgG autoantibodies, as it depletes both naïve and activated B cells, but not memory B cells. 51 Considering that pathogenic autoantibodies in HF are mostly of the IgG3 class and that B-cell subsets in this context are largely unknown, further research is necessary to justify its use in HF.…”
Section: B Cells As a Therapeutic Target In Heart Failurementioning
confidence: 99%